Sonoma Pharmaceuticals (SNOA) Competitors $3.43 +0.18 (+5.54%) Closing price 04:00 PM EasternExtended Trading$3.42 -0.01 (-0.15%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SNOA vs. DRRX, TENX, ENLV, PASG, CDIO, PMN, RNXT, CARA, GRCE, and CLDIShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include DURECT (DRRX), Tenax Therapeutics (TENX), Enlivex Therapeutics (ENLV), Passage Bio (PASG), Cardio Diagnostics (CDIO), ProMIS Neurosciences (PMN), RenovoRx (RNXT), Cara Therapeutics (CARA), Grace Therapeutics (GRCE), and Calidi Biotherapeutics (CLDI). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. DURECT Tenax Therapeutics Enlivex Therapeutics Passage Bio Cardio Diagnostics ProMIS Neurosciences RenovoRx Cara Therapeutics Grace Therapeutics Calidi Biotherapeutics DURECT (NASDAQ:DRRX) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Do insiders and institutionals hold more shares of DRRX or SNOA? 28.0% of DURECT shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 3.2% of DURECT shares are held by company insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, DRRX or SNOA? DURECT has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Is DRRX or SNOA more profitable? Sonoma Pharmaceuticals has a net margin of -26.82% compared to DURECT's net margin of -198.58%. Sonoma Pharmaceuticals' return on equity of -68.98% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets DURECT-198.58% -300.62% -65.17% Sonoma Pharmaceuticals -26.82%-68.98%-26.39% Does the MarketBeat Community prefer DRRX or SNOA? DURECT received 100 more outperform votes than Sonoma Pharmaceuticals when rated by MarketBeat users. However, 67.50% of users gave Sonoma Pharmaceuticals an outperform vote while only 61.96% of users gave DURECT an outperform vote. CompanyUnderperformOutperformDURECTOutperform Votes31661.96% Underperform Votes19438.04% Sonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% Which has stronger valuation and earnings, DRRX or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDURECT$8.59M2.89-$27.62M-$0.61-1.31Sonoma Pharmaceuticals$13.97M0.40-$4.84M-$4.02-0.85 Do analysts rate DRRX or SNOA? DURECT currently has a consensus price target of $5.00, suggesting a potential upside of 525.00%. Given DURECT's stronger consensus rating and higher probable upside, equities research analysts clearly believe DURECT is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DURECT 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor DRRX or SNOA? In the previous week, DURECT and DURECT both had 1 articles in the media. Sonoma Pharmaceuticals' average media sentiment score of 0.48 beat DURECT's score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DURECT 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sonoma Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySonoma Pharmaceuticals beats DURECT on 10 of the 17 factors compared between the two stocks. Remove Ads Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.54M$4.48B$5.73B$8.12BDividend YieldN/A29.39%4.41%4.09%P/E Ratio-0.8529.5624.4819.28Price / Sales0.4051.71402.1489.10Price / CashN/A51.0838.1134.64Price / Book1.146.306.904.38Net Income-$4.84M$67.64M$3.18B$247.04M7 Day Performance-2.28%6.75%0.81%2.01%1 Month Performance40.34%-5.35%0.40%-8.31%1 Year Performance2,265.52%22.13%13.84%5.72% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals0.9273 of 5 stars$3.43+5.5%N/A+2,238.1%$5.54M$13.97M-0.85180News CoverageGap UpDRRXDURECT3.7263 of 5 stars$0.80-6.9%$5.00+524.2%-40.7%$24.87M$8.59M-1.3180Upcoming EarningsAnalyst ForecastNews CoverageTENXTenax Therapeutics2.0371 of 5 stars$6.23-2.8%$18.00+188.9%+60.7%$24.70MN/A0.009ENLVEnlivex Therapeutics3.1082 of 5 stars$1.15-5.7%$9.50+726.1%-72.7%$24.62MN/A-1.1770PASGPassage Bio2.8952 of 5 stars$0.39+1.0%$7.50+1,823.1%-69.2%$24.24MN/A-0.33130CDIOCardio Diagnostics2.8214 of 5 stars$0.46+9.1%$2.00+332.2%-66.1%$24.13M$35,688.000.001Short Interest ↓Positive NewsPMNProMIS Neurosciences1.6403 of 5 stars$0.74-4.4%N/A-62.6%$24.03MN/A-7.355Short Interest ↓Gap UpRNXTRenovoRx1.3279 of 5 stars$1.00+1.4%$9.00+800.0%-27.5%$24.00MN/A-1.756Positive NewsGap DownCARACara Therapeutics4.0048 of 5 stars$5.12-0.2%$27.84+443.8%-52.2%$23.42M$7.14M-0.2480GRCEGrace Therapeutics2.5207 of 5 stars$2.29+5.0%$12.00+424.0%N/A$23.22MN/A-1.97N/APositive NewsCLDICalidi Biotherapeutics2.1778 of 5 stars$0.87+2.2%$16.67+1,817.9%N/A$23.00M$50,000.000.0038Gap Up Remove Ads Related Companies and Tools Related Companies DURECT Competitors Tenax Therapeutics Competitors Enlivex Therapeutics Competitors Passage Bio Competitors Cardio Diagnostics Competitors ProMIS Neurosciences Competitors RenovoRx Competitors Cara Therapeutics Competitors Grace Therapeutics Competitors Calidi Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 3/19/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
